Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KCT-0809 in Dry Eye Syndrome
NCT01427816Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozagrel in dry eye syndrome (DED) (3 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Corneal staining score at 6 weeks. Status: completed.
02
Drugs
ozagrel
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT01427816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01427816.